Clovis Oncology Inc. called a halt late Friday to its phase II open-label monotherapy trial evaluating Rubraca (rucaparib) in recurrent metastatic bladder cancer (Atlas), based on a data monitoring committee recommendation that had reviewed the preliminary efficacy data.